-  Main Exclusion at Screening:<br/><br/>               1. Subject in the opinion of the investigator has clinically significant Bladder<br/>                  Outlet Obstruction (BOO).<br/><br/>               2. Subject has significant Post-void residual (PVR) volume (PVR > 150 ml).<br/><br/>               3. Subject has significant stress incontinence or mixed stress/urgency incontinence<br/>                  where stress is the predominant factor as determined by the investigator<br/><br/>               4. Subject has an indwelling catheter or practices intermittent self<br/>                  catheterization.<br/><br/>               5. Subject has evidence of a UTI.<br/><br/>               6. Subject has chronic inflammation such as interstitial cystitis, bladder stones,<br/>                  previous pelvic radiation therapy, or previous or current malignant disease of<br/>                  the pelvic organs<br/><br/>               7. Subject has moderate to severe hepatic impairment<br/><br/>               8. Subject has severe renal impairment or End Stage Renal disease<br/><br/>               9. Subject has a clinically significant abnormal Electrocardiogram (ECG)<br/><br/>              10. Subject has a concurrent malignancy or history of cancer (except noninvasive<br/>                  skin cancer) within the last 5 years prior to screening.<br/><br/>              11. Subject has a QTcF interval > 450 ms for males or > 470 ms for females or is at<br/>                  risk of QT prolongation (e.g., family history of long QT syndrome,<br/>                  hypokalaemia).<br/><br/>              12. Subject has received intravesical treatment in the past 12 months with e.g.,<br/>                  botulinum toxin, resiniferatoxin, capsaicin.<br/><br/>              13. Subject has severe uncontrolled hypertension, which is defined as a sitting<br/>                  average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood<br/>                  pressure ≥ 110 mmHg.<br/><br/>          -  Main Exclusion at Randomization (visit 3):<br/><br/>               1. Subject has achieved 100% continence from Visit 2 to Visit 3 (no incontinence<br/>                  episodes are recorded in the 3 day diary administered for 3 days prior to Visit<br/>                  3).<br/><br/>               2. Subject does not desire an increase in study medication.<br/><br/>               3. Subject has an average total daily urine volume > 3000ml as recorded in the<br/>                  micturition diary.<br/><br/>               4. Subject has severe uncontrolled hypertension, which is defined as a sitting<br/>                  average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood<br/>                  pressure ≥ 110 mmHg.<br/><br/>               5. Subject has a clinically significant abnormal ECG<br/>